Federal grants to Rise Therapeutics LLC
Rise Therapeutics LLC in Rockville, Maryland received $26.5 million in federal grants from fiscal 2021 to 2025, across 14 awards. Its largest program was Diabetes, Digestive, and Kidney Diseases Extramural Research, with $9.1 million. In fiscal 2025 it was awarded $2.9 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$26.5 million
- Awards14
- Awarded in FY 2025$2.9 million
- Largest award$2.9 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 5 | $4.2 million |
| FY 2022 | 8 | $6.3 million |
| FY 2023 | 9 | $7.5 million |
| FY 2024 | 7 | $5.7 million |
| FY 2025 | 4 | $2.9 million |
Programs that fund Rise Therapeutics LLC
| Program | Awards | Amount |
|---|---|---|
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 5 | $9.1 million |
| Allergy and Infectious Diseases Research | 4 | $8.9 million |
| Oral Diseases and Disorders Research | 2 | $3.3 million |
| Cancer Treatment Research | 1 | $2.4 million |
| Aging Research | 1 | $2.4 million |
| National Center for Advancing Translational Sciences | 1 | $282,514 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 14 | $26.5 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| A novel immunologically enhanced probiotic for treating rheumatoid arthritis - project summary our goal is to commercialize R-2487 as a novel, orally administered therapy for long-term disease remission of rheumatoid arthritis (RA). Ra is a chronic, systemic inflammatory disorder affecting up to 1% | Allergy and Infectious Diseases Research | February 22, 2021 | $2.9 million |
| A novel probiotic for the treatment of sjogren's syndrome - project summary our goal is to develop a novel, immunologically enhanced l. Lactis probiotic-based therapeutic for the treatment of sjÖgren’s syndrome (SJS). Sjs is a progressive, chronic autoimmune disease characterized by inflammatory cel | Oral Diseases and Disorders Research | May 12, 2021 | $2.9 million |
| A novel microbiome-based immune-modulator that potentiates cancer checkpoint therapy - project summary the goal of this project is to develop a novel oral drug, R-5780, which engages microbiome-associated pattern recognition receptors (PRRS) to enhance the activity of immune checkpoint inhibitor (ic | Cancer Treatment Research | March 31, 2021 | $2.4 million |
| A novel immunological-directed biotherapy for treating rheumatoid arthritis - project summary our goal is to develop a novel, immunological-directed l. Lactis probiotic-based therapeutic for the treatment of rheumatoid arthritis (RA). Ra is a chronic, systemic inflammatory disorder affecting up to 1 | Aging Research | September 4, 2023 | $2.4 million |
| A novel immunological-directed live biotherapy product for treating ulcerative colitis - project summary the goal of this project is to develop a novel immunological-directed live biotherapeutic product (LBP) that leverages natural microbiome pathways to inhibit gut inflammatory processes for the tr | Diabetes, Digestive, and Kidney Diseases Extramural Research | July 4, 2022 | $2.3 million |
| A novel immunological-directed synthetic biology-based drug for the treatment of multiple sclerosis - project summary our goal is to develop a novel, immunological-directed synthetic biology-based therapeutic for the treatment of multiple sclerosis (MS). Ms is a devastating characterized by an exace | Allergy and Infectious Diseases Research | April 24, 2023 | $2.1 million |
| A novel immunologically directed probiotic for the treatment of type 1 diabetes - project summary our goal is to develop a novel, immunologically-directed l. Lactis probiotic-based therapeutic for the treatment of type 1 diabetes (T1D)1. T1D is a devastating disease and there is no curative treatmen | Diabetes, Digestive, and Kidney Diseases Extramural Research | June 24, 2022 | $2.1 million |
| A novel synthetic biology-derived microbiome therapeutic to treat viral-induced acute respiratory distress syndrome (ARDS) - project summary acute respiratory distress syndrome (ARDS) is a severe life-threatening complication that can be caused by viral infection. The disease is characterized by cyt | Allergy and Infectious Diseases Research | January 17, 2023 | $2.0 million |
| R-5280, a novel modified superior resistant starch therapy for type 1 diabetes - project summary type 1 diabetes (T1D) is a devastating disease and there is no current curative treatment, with insulin being the only product available. T1D affects not only glycemic control but also many important asp | Diabetes, Digestive, and Kidney Diseases Extramural Research | August 11, 2023 | $2.0 million |
| A novel engineered probiotic for the prevention of clostridium difficile infection | Allergy and Infectious Diseases Research | June 29, 2021 | $1.9 million |
Questions people ask
How much federal grant money does Rise Therapeutics LLC get?
$26.5 million in 14 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Rise Therapeutics LLC the most?
The Department of Health and Human Services, with $26.5 million in 14 awards.
What is Rise Therapeutics LLC's largest federal grant?
$2.9 million under Allergy and Infectious Diseases Research, with its first action in the period on February 22, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Rise Therapeutics LLC?
Its largest are Diabetes, Digestive, and Kidney Diseases Extramural Research, Allergy and Infectious Diseases Research and Oral Diseases and Disorders Research.
Other grant recipients in Rockville
- X Energy, LLC
- Abt Global LLC
- Westat, Inc.
- The United States Pharmacopeial Convention, Inc.
- Montgomery College
- JBS International, Inc.
- Child Trends, Incorporated
- Sanaria Inc.
Largest federal grant recipients in Maryland · Federal grants in Maryland